Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 77 clinical trials
Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies

-arterial chemoembolization ("TACE") with or without the utilization of Surefire

carcinoma
neutrophil count
TACE
doxorubicin
chemoembolization
  • 13 views
  • 24 Mar, 2022
  • 1 location
Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC (SOURCE)

This trial is a multi-center, phase III, randomized (1:1) clinical trial. The aim is to explore the efficacy and safety of Sorafenib combined with transarterial chemoembolization as adjuvant

chemoembolization
tyrosine
TACE
sorafenib
  • 1 views
  • 16 Feb, 2022
  • 1 location
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma

Transarterial chemoembolization (TACE) based on drug-eluting beads (DEB-TACE) is widely used for unresectable hepatocellular carcinoma (HCC). However, the long-term survival is still low after

  • 0 views
  • 16 Feb, 2021
  • 1 location
Comparing Re-TACE Versus SABR for Post-prior-TACE Incompletely Regressed HCC: a Randomized Controlled Trial (TASABR) (TASABR)

Till now, trans-arterial chemoembolization (TACE) is still one of the common modalities in treating hepatocellular carcinoma patients with unresectable intermediate stage. However, residual

cancer
platelet count
TACE
neutrophil count
  • 12 views
  • 25 Feb, 2022
  • 1 location
Surgery Versus Non-Surgical Treatment for Clinical Complete Responders After Non-Curative Therapy for Hepatocellular Carcinoma

immunotherapy for unresectable HCC has achieved an objective response rate of about 30%. In addition, transarterial hepatic artery chemoembolization and hepatic artery infusion chemotherapy have further

serum bilirubin
tumor cells
metastasis
cancer
  • 0 views
  • 18 May, 2022
  • 1 location
Neo-TACE-HAIC for BCLC B Stage HCC

Hepatocellular carcinoma (HCC) patients is a common disease in the East Asia. Although BCLC (Barcelona clinical liver cancer) system recommend to transarterial chemoembolization (TACE) for BCLC

liver cancer
hepatic arterial infusion
TACE
folfox
cancer
  • 0 views
  • 26 Jan, 2021
  • 1 location
A Study on the Angioarchitecture of Hepatocellular Carcinoma

general, there is still much room for improvement, especially for large size tumors. From the studies on Transarterial chemoembolization (TACE), it is known that the treatment outcome is affected by the

hepatectomy
liver cancer
TACE
cancer
measurable disease
  • 0 views
  • 28 Feb, 2022
  • 1 location
Neo-TACE-HAIC for PVTT-HCC

transartery chemoembolization (TACE). Recently, FOLFOX (Oxaliplatin and 5-fluorouracil) based hepatic artery infusion chemotherapy (HAIC) exhibited high response rate for advanced HCC. Pilot

liver cancer
hepatic arterial infusion
TACE
tumour thrombus
folfox
  • 0 views
  • 26 Jan, 2021
  • 1 location
PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm Phase 2 Clinical Trial

than 20% of newly diagnosed patients can undergo radical resection. Our latest study showed that 48% potentially resectable HCC received hepatectomy after transarterial chemoembolization plus FOLFOX

TACE
folfox
  • 0 views
  • 30 Sep, 2021
  • 1 location
Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01) (ISBRT01)

months. It has been demonstrated that first-line treatment with transarterial chemoembolization plus radiotherapy could provide more favorable survival than sorafenib alone. However, intrahepatic

liver disease
hepatic arterial infusion
neutrophil count
TACE
sorafenib
  • 0 views
  • 18 Feb, 2022
  • 1 location